Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study

PURPOSE: In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing’s disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor volume, and improved clinical sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacroix, André, Gu, Feng, Schopohl, Jochen, Kandra, Albert, Pedroncelli, Alberto M., Jin, Lixian, Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181422/
https://www.ncbi.nlm.nih.gov/pubmed/31875276
http://dx.doi.org/10.1007/s11102-019-01021-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181422/
https://www.ncbi.nlm.nih.gov/pubmed/31875276
http://dx.doi.org/10.1007/s11102-019-01021-2

Ejemplares similares